Actual problems in occupational lung diseases
Abstract
Respiratory diseases are most common among occupational pathology. This review provides the latest scientific and practical progress in the field of occupational lung diseases and the most actual research trends in this area. Studies conducted in Novosibirsk State Medical University and Research Institute of Internal and Preventive Medicine were presented. Molecular, genetic and proteomic studies are the fundamental for improving prophylaxis, diagnosis and treatment of these diseases. Asthma chronic obstructive pulmonary disease (COPD) phenotyping provides the possibility to individualize treatment and management of such patients and proposed to be investigated in relation to environmental factors.
Key words
References- Artiomova L.V., Kuzmina L.P., Sorkina N.S., et al. Topical aspects of contemporary forms of occupational bronchial asthma / Occupation Medicine and Industrial ecology=Medicina truda i promyshlennaja jekologija 2014. (7) 19-24. . [In Russian]
- Russian Rheumatology Association [Electronic resource]. National Federal guidelines for the rheumatic diseases. URL http://www.rheumatolog.ru/experts/klinicheskie-rekomendacii. . [In Russian]
- Pilishenko V.A., Glushkova N.Ju., Kurkin D.P. The state of occupational diseases in the Russian Federation in 2011. Information Collection analytical materials. M.: Federal'nyj centr gigieny i jepidemiologii Rospotrebnadzora. 2012. – 48 P. . [In Russian]
- Order of the Ministry of Health and Social Development of 27.04.2012№417n "On approval of the list of occupational diseases", registered in the Ministry of Justice 15.05.2012г, №24168. [In Russian]
- ILO Recommendation number 194. On the list of occupational diseases, notification of occupational accidents and occupational diseases and their registration. [Electronic resource]. URL: http://www.conventions.ru/view_base.php?id=625 . [In Russian]
- Smirnova E.L., Poteryaeva E.L., Nikiforova N.G etc. Prediction of the cause of pneumoconiosis in the post-exposure period based on an assessment of individual risk factors // Occupation and health: Proceedings of the IX All-Russian Congress and IV All-Russian Congress of occupational medicine specialists. – М., 2010. – P.. 474–476. . [In Russian]
- Fomina V.S., Kuz'mina L. P. Matrix metalloproteinase (pro-MMP-1, MMP-2,8) and their inhibitors (TIMP-1) evaluation in patients with occupational lung disease / Occupation Medicine and Industrial ecology=Meditsina truda i promyshlennaya ekologiya. 2010 (7) 29-33. [In Russian]
- A.G. Chuchalin, L.A. Shpagina, O.S. Vasilyeva etc. Occupational chronic obstructive pulmonary disease / Occupational lung diseases. National guidelines. M.: GEOTAR, 2015. 293 – 338. [In Russian]
- L.A.Shpagina, M.I.Voevoda, O.S.Kotova etc.. Occupational chronic obstructive pulmonary disease from the point of molecular genetic research// Bulletin of physiology and pathology of Respiration=Byulleten' fiziologii i patologii dykhaniya. 2013. (49) 8–15. . [In Russian]
- Agusti A., Bel E., Thomas M. et al. Treatable traits: toward precision medicine of chronic airway diseases // Eur Respir J. 2016 47 410-419.
- Annesi-Maesano I., Lundbäck B., Viegi G. Respiratory Epidemiology. ERS. 2014. – 273 P.
- Beier J., Kirsten A.M., Mróz R. et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study // COPD. 2013. 10 511-522.
- Brüske I., Thiering E., Heinrich J. et al. Biopersistent granular dust and chronic obstructive pulmonary disease: a systematic review and meta-analysis // PLoS One. 2013. 8 e80977.
- Calverley P.M., Rabe K.F., Goehring U.M. et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials// Lancet 2009. 374 685-694.
- Centers for Disease Control and Prevention (CDC). Pneumoconiosis and advanced occupational lung disease among surface coal miners--16 states, 2010-2011 // MMWR Morb Mortal Wkly Rep. 2012. 61 431–434.
- Chapman K.R.Beeh K.M., Beier J et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study // BMC Pulm Med. 2014. 14 4.
- Eisner M.D., Anthonisen N., Coultas D. et al. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease // Am J Respir Crit Care Med. 2010. 182 693-718
- Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (revised 2016). Available from URL: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. 2016.
- McGrath K.W., Icitovic N., Boushey H.A. et al., A large subgroup of mild-to-moderate asthma is persistently noneosinophilic // Am J Respir Crit Care Med. 2012. 185 612-619.
- de Jong K., Boezen H.M., Kromhout H. et al. Pesticides and other occupational exposures are associated with airway obstruction: the LifeLines cohort study // Occup Environ Med. 2014. 71 88-96.
- Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison // Eur Respir J 2011. 37 273-279.
- Kukkonen M.K., Tiili E., Vehmas T. et al. Association of genes of protease-antiprotease balance pathway to lung function and emphysema subtypes // BMC Pulm Med. 2013. 13. 36.
- Lavaud F., Bonniaud P., Dalphin J.C. et al. Usefulness of omalizumab in ten patients with severe occupational asthma // Allergy. 2013. 68. 813-5.
- Mahler D.A., Decramer M., D'Urzo A. et al., Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study // Eur Respir J. 2014. 43 1599-1609.
- Malo J.L., Tarlo S.M., Sastre J. et al. An official American Thoracic Society Workshop Report: presentations and discussion of the fifth Jack Pepys Workshop on Asthma in the Workplace. Comparisons between asthma in the workplace and non-work-related asthma. // Ann Am Thorac Soc. 2015 12 S99-S110
- Mariotti F., Ciurlia G., Spaccapelo L. et al., A Two-Period Open-Label, Single-Dose Crossover Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Between Cimetidine and Inhaled Extrafine CHF 599 // Eur J Drug Metab Pharmacokinet. 2016 Available from URL: http://link.springer.com/article/10.1007%2Fs13318-016-0345-2
- Martinez F.J., Boscia J., Feldman G. et al., Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial // Respir Med. 2013. 107 550-559.
- Miravitlles M., Soler-Cataluna J.J., Calle M., Soriano J.B. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice // Eur Respir J 2013. 41 1252-1256
- Normansell R., Walker S., Milan S.J. et al. Omalizumab for asthma in adults and children // Cochrane Database Syst Rev. 2014. (1) CD003559.
- Paulin L.M., Diette G.B., Blanc P.D. et al. Occupational exposures are associated with worse morbidity in patients with chronic obstructive pulmonary disease // Am J Respir Crit Care Med. 2015. 191 557-565.
- Pavord I.D., Lettis S., Locantore N. et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD // Thorax. 2016. 71 118-125.
- Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial // Lancet. 2012. 380. 651-659.
- Postma D.S., Roche N., Colice G. et al., Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD // Int J Chron Obstruct Pulmon Dis. 2014. 9 1163-1186.
- Rodríguez E., Ferrer J., Zock J.P. et al., Lifetime occupational exposure to dusts, gases and fumes is associated with bronchitis symptoms and higher diffusion capacity in COPD patients // PLoS One. 2014. 9 e88426.
- Singh D., Jones P.W., Bateman E.D. et al., Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study // BMC Pulm Med. 2014. 14 178
- Singh D., Kolsum U., Brightling C.E. et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics // Eur Respir J. 2014.44 1697-1700.
- Singh D., Gaga M., Schmidt O. et al., Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies // Respir Res. 2016. 17. 73.
- Suissa S., Dell'Aniello S., Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality // Thorax. 2012. 67 957-963.
- Taniguchi H., Ebina M., Kondoh Y. et al. Pirfenidone in idiopathic pulmonary fibrosis // Eur Respir J. 2010. 4 821-829.
Shpagina L.A. – doctor of medical sciences, professor, head of the department of internal medicine and medical rehabilitation, e-mail: mkb-2@yandex.ru